ArticleJACC. Case reports2025
Apparent End-Stage Heart Failure Forced Toward a Successful Myocardial Recovery.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStrategies to promote myocardial recovery from cardiogenic shock (CS) remain understudied. CASE SUMMARY: A 51-year-old woman with recently diagnosed heart failure (left ventricular ejection fraction <10%) presented in CS requiring milrinone and temporary mechanical circulatory support (t-MCS). Multimodality testing revealed no specific etiology, but cardiac positron emission tomography-flourodeoxyglucose imaging showed uptake in the colon. Biopsy was performed with tubulovillous adenoma with high-grade dysplasia necessitating colectomy/colostomy. Malignancy was excluded, but heart replacement therapy was deemed high risk due to colostomy. t-MCS was weaned, and inotropes were discontinued after months of guideline-directed medical therapy (guideline-directed medical therapy) titration. Current LVEF is in the range of 35% to 39%, and the patient remains ambulatory. DISCUSSION: This case illustrates "forced recovery" via prolonged inotrope-supported guideline-directed medical therapy due to heart replacement therapy contraindications. TAKE-HOME MESSAGES: Native heart recovery is possible even in CS requiring t-MCS, emphasizing the need for individualized strategies. Research is needed to identify predictors of recovery and strategies for native heart recovery-focused approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.